A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Key facts
- Where
- Bay City, Bellaire, Beverly, Brighton, Cape Coral, Cumming, Dearborn, East Syracuse, Hollywood, Hoover, Houston, Irvine, Kokomo, Las Vegas, Marietta, Miami, Miami Lakes, Murfreesboro, New York, Plymouth Meeting, Richmond, Saint Joseph, San Antonio, Santa Monica, Sherman Oaks, Spokane, Stonecrest, Stony Brook, Sunnyvale, Tampa, Troy, and West Jordan, United StatesSee the 34 sites
- Phase
- Phase 3
Where in United States
- Great Lakes Research Group, Inc.Bay City, United StatesNo longer taking part
- University of Texas Physicians - Bellaire StationBellaire, United StatesNo longer taking part
- Allcutis Research LLCBeverly, United StatesNo longer taking part
- Metro Boston Clinical PartnersBrighton, United StatesNo longer taking part
- Renaissance ResearchCape Coral, United StatesNo longer taking part
- Cleaver Medical GroupCumming, United StatesNo longer taking part
- Wayne State University Physician Group DermatologyDearborn, United StatesNo longer taking part
- Empire DermatologyEast Syracuse, United StatesNo longer taking part
- Encore Medical Research LLCHollywood, United StatesNo longer taking part
- Cahaba DermatologyHoover, United StatesNo longer taking part
- Center for Clinical StudiesHouston, United StatesNo longer taking part
- University of California, IrvineIrvine, United StatesNo longer taking part
- Options Research Group, LlcKokomo, United StatesNo longer taking part
- JDR Dermatology ResearchLas Vegas, United StatesNo longer taking part
- Dermatology and Surgery Specialists of North AtlantaMarietta, United StatesNo longer taking part
- Savin Medical Group, RcMiami, United StatesNo longer taking part
- Skin Research of South Florida, LlcMiami, United StatesNo longer taking part
- San Marcus Research Clinic, Inc.Miami Lakes, United StatesNo longer taking part
- International Clinical Research - Tennessee LLCMurfreesboro, United StatesNo longer taking part
- Sadick Dermatology Sadick Research GroupNew York, United StatesNo longer taking part
- Dermatology Associates of Plymouth MeetingPlymouth Meeting, United StatesNo longer taking part
- Clinical Research Partners Llc Crp Richmond Forest Avenue Office Building LocationRichmond, United StatesNo longer taking part
- Medisearch Clinical TrialsSaint Joseph, United StatesNo longer taking part
- Progressive Clinical ResearchSan Antonio, United StatesNo longer taking part
- Clinical Science Institute Clinical Research Specialists IncSanta Monica, United StatesNo longer taking part
- Cura Clinical ResearchSherman Oaks, United StatesNo longer taking part
- Dermatology Specialists of SpokaneSpokane, United StatesNo longer taking part
- Pivotal Research SolutionsStonecrest, United StatesNo longer taking part
- Derm Research Center of New York, Inc.Stony Brook, United StatesNo longer taking part
- Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale CenterSunnyvale, United StatesNo longer taking part
- ForCare Clinical ResearchTampa, United StatesNo longer taking part
- Olympian Clinical ResearchTampa, United StatesNo longer taking part
- Revival Research Institute, Llc DermatologyTroy, United StatesNo longer taking part
- Jordan Valley Dermatology CenterWest Jordan, United StatesNo longer taking part
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06113445EU 2023-505782-86-00
- Record updated
- 25 August 2026
- Original description
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Inclusion: Aged ≥ 18 years; Clinical diagnosis of nonsegmental vitiligo and meet the following:; T-BSA ≥ 5%; T-VASI score ≥ 4; F-BSA ≥ 0.5%; F-VASI score ≥ 0.5; Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit; Willingness to avoid pregnancy or fathering children.
Exclusion: Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1; Spontaneous and significant repigmentation within 6 months prior to screening; Other forms of vitiligo or skin depigmentation disorders; History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo; Evidence of infection with TB, HBV, HCV or HIV; History of failure to JAK inhibitor treatment of any inflammatory disease; Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies; Laboratory values outside of the protocol-defined ranges; Other protocol-defined Inclusion/Exclusion Criteria may apply; Clinically significant abnormal TSH or free T4 at screening; Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®; Women who are pregnant, considering pregnancy, or breast feeding.